CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
Completed · Phase 2
Conditions studied: Multiple Myeloma
In brief
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
Key facts
- Study ID
- NCT00044018
- Run by
- Celgene
- People needed
- 102
- Starts
- 2002-04-01
- Expected to finish
- 2007-02-15
- Last updated by the study team
- 2019-11-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- H Lee Moffit Cancer Center — Tampa, Florida, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- St Vincent's Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.